Navigation Links
HudsonAlpha investigator develops rapid response swine flu test
Date:5/8/2009

Huntsville, Ala. Dr. Jian Han, faculty investigator at the HudsonAlpha Institute for Biotechnology, has completed development of a rapid response, molecular-level assay for swine flu, the current strain of the H1N1 family of the influenza virus. The test, which can confirm swine flu in less than six hours, will be incorporated into a viral respiratory panel made available by Diatherix Laboratories. The panel will detect the current strain of swine flu, as well as Influenza A, Influenza B and other viruses.

Because of the potential for the current strain of virus to mutate, Han, who holds both M.D. and Ph.D. degrees, included four swine flu targets in the diagnostic tool. "So even if there is some molecular-level mutation and one or two targets are rendered useless, we still have other targets that will provide a correct answer," said Han.

The proprietary technology used in the Diatherix panel is called Target Enriched Multiplex Polymerase Chain Reaction (Tem-PCR). Tem-PCR, originally developed by Han, has the capability to identify multiple pathogens, both viral and bacterial. This technology can test for multiple genetic targets at one time and is the only rapid molecular test that can subtype multiple viral and bacterial strains in a single test.

According to Dennis Grimaud, chief executive officer for Diatherix Laboratories, the viral respiratory panel allows physicians to quickly distinguish between patients who have swine flu and those who present with similar symptoms. "This enables physicians to provide proper therapy in a timely manner," noted Grimaud. "A rapid confirmation can also mitigate many of the negative economic and social impacts associated with infectious disease outbreaks," he added, "ranging from school closures to reductions in retail traffic, travel and tourism."

Diatherix is currently making the test available to hospitals, private physician practices and public health departments. Patient s
'/>"/>

Contact: Holly Ralston McClain
hmcclain@hudsonalpha.org
256-327-0425
HudsonAlpha Institute for Biotechnology
Source:Eurekalert

Page: 1 2

Related biology news :

1. 18 young scientists join EMBO Young Investigator network
2. Yale chemist receives NIH Young Investigator Award for antibody targeting
3. Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young investigators
4. Leemor Joshua-Tor, PhD, CSHL biologist and WSBS dean, is named an HHMI Investigator
5. 4 Stanford faculty named Howard Hughes Medical Institute Investigators
6. Erich Jarvis named Howard Hughes Investigator
7. 2 University of Illinois researchers named HHMI investigators
8. BWF awards $7 million to infectious disease investigators
9. Childrens National researcher receives ACCP Distinguished Investigator Award
10. TGen investigators devise faster, cheaper way of analyzing the human genome
11. 12 outstanding young scientists named as EMBO Young Investigators

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...eries from collapsing have been true life-savers. ...eeded -- once the arteries are strengthened, they ...ice but to leave them in place. , Prof. Meital Z...omedical Engineering has developed a new patent-pe...,re needed, then dissolves. , "Our new composite...
(Date:11/24/2009)...secrets of the earth,s history locked in its icy d...tle information on the environments that have been.... Now, a team of researchers from nine institution...$10 million dollars by the National Science Founda...rally. These scientists will drill through the Wes...
(Date:11/23/2009)...vidence that the "synergistic" effect of early-lif...on and indoor endotoxin causes more harm to develo... , Environmental health scientists at the Univer...hown that children exposed to both high levels of ...ing early life are six times more likely to experi...
Breaking Biology News(10 mins):A coating for life 2LSU gets to the bottom of things -- in Antarctica 2Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2A Milestone of Opportunity for VNUS Medical Technologies 48130 1A Milestone of Opportunity for VNUS Medical Technologies 48130 2A Milestone of Opportunity for VNUS Medical Technologies 48130 3Providence Health 26 Services Increases Revenue by 2435 Million Using Concuity ClearContracts 12502 1Providence Health 26 Services Increases Revenue by 2435 Million Using Concuity ClearContracts 12502 2Providence Health 26 Services Increases Revenue by 2435 Million Using Concuity ClearContracts 12502 3Forterus Inc Announces Free Outpatient Treatment to Military Veterans Back from War Zones 48129 1Forterus Inc Announces Free Outpatient Treatment to Military Veterans Back from War Zones 48129 2
...unisia, supported by the European Commission, high... health in countries bordering the Mediterranean S...rtance of Euro-Mediterranean partnerships in order...e sciences ?in particular following the mapping of...rove scientific knowledge and approaches to improv...
... radiotherapy, on a cellular scale. Antibodies cou..., bind to and kill cancerous cells. Provided that ...ce between normal and cancerous cells; this is not... for lymphoma that takes a fraction of the time of...caused tumors to shrink in 95 percent of patients,...
...called CD14 binds to substances liberated from the...nisms. In a report published in the Journal of Bio...heir elucidation of three-dimensional structure of...d to certain bacterial products. , The research ap...ssue of the Journal of Biological Chemistry, an Am...
Other Biology News:Measuring the impact of post-genomics on Mediterranean populations 2New Treatment Rivals Chemotherapy For Lymphoma, Study Finds 2New Treatment Rivals Chemotherapy For Lymphoma, Study Finds 3Scientists solve structure of key protein in innate immune response 2
(Date:11/24/2009)... Health care employment grew by 29,000 jobs in Oc...consistent growth during the U.S. recession. Howev...ble, and health systems are coming closer to havin...st administrators. , (Voc...ntinued growing in October despite the shedding of...
(Date:11/24/2009)...I, Nov. 24 /PRNewswire-Asia/ -- NOD Pharmaceutical...ice (PTO) has allowed the patent application for,i..., NOD technology is a highly efficient ap...o-adhesive nano-particles to enable oral delivery ... technology is a platform technology,that can be a...
(Date:11/24/2009)...HAI, Nov. 24 /PRNewswire-Asia/ -- Shanghai Biolaxy...istration (SFDA) has approved the,investigational ...oject,(Nodlin), an innovative insulin formulation ...y to initiate its first phase I clinical study. ,...high blood glucose and poor,metabolism. The compli...
(Date:11/24/2009)...The FBI recently approved the Promega PowerPlex 16...n or generating DNA records for the National DNA I...I USA (PRWEB) -- The FBI recently approved the Pro...ratories participating in, or generating DNA recor... currently contains more than seven million profil...
Breaking Biology Technology:The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Biolaxy Secures IND Approval for Oral Insulin 2NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2
... CITY, New Jersey, November 26, Rosetta Genomics (...third quarter financial results on December 5, 200...will host a conference call with a,simultaneous we...Friday,December 5. , To access the live conf...al 1-866-966-5335; international participants may ...
...E, Nov. 26 Spectrum,Pharmaceuticals, Inc. (Nasdaq...CTIC )(MTA: CTIC) announced today they have entere...nture, RIT Oncology LLC, to commercialize and,deve... United States.,ZEVALIN, a radioimmunotherapeutic ...by Cell Therapeutics, Inc. (CTI) for the treatment...
...Equels, President and Managing,Director of the Equ...ectors,for Hemispherx BioPharma, Inc. (Amex: HEB... engaged in the manufacture and clinical developme... and immune-based disorders. , Equels, legal...r emphasis,on civil racketeering, business torts a...
Other Biology Technology:Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results 2Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 2Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 3Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 4Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 5Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 6Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 7Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 8Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors 2Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors 3
Stirbar, Trans-Blot Plus cell from Bio-Rad
Super Cooling Coil, Trans-Blot cell from Bio-Rad
Criterion Staining and Blotting Trays, with lids, 12 from Bio-Rad
...ting a wide range of next-generation features into...andard for flexible laboratory solutions. It puts ...ng, dilution, dispensing, and integrations into a...exible as it is efficient and economical. The Biom...
Biology Products: